Swiss pharmaceutical giant Ithina said on Wednesday to 5.3 billion dollars to develop Danish biotechnology Zealand PharmaA candidate for obese drugs, because two companies, because two companies try to compete in a medicine market for weight loss.
The deal is two companies and Petleres, the Pharma of Zealand Amylin analogue As a personal therapy, a dozing dose combination with a leading gesture ASSET CT-388 of Roch.
According to the agreement, Zealand Pharma is 1.65 billion tenge.
Zealand’s pharma shares increased by 38%, and Roh shares are 3.6% higher.
Obesity Applicable shares Novo nordiskAt the same time, at the session on Wednesday, 4.3% was detoured.
Zealand, General Director and President of the President, told CNBC, and the agreement said that the two companies are “confidence in leadership in the future.”
“Roch convinced us that he had an ambitions in this therapeutic space,” said Scenzberg told CNBC by video call on Wednesday.
Manu Chagravarti, the development of the Global Therapy region General and cardiovascular, kidney and metabolic (CVRM) productive.
Stansberg Zealand said the Zelensberg was “at a high level” since the beginning of the partnership discussions last year. However, he noted that the Switzerland was “the most important” Previous events In the market of obese medicine, including the purchase of GLP-1 Maker Carmote Therapy.
According to him, the partnership with market leaders was “unlikely”, which was “unlikely”, and gave about fraching and cylies for GLP-1 fatty drug fraching.
Amerial America Sequities said that Wednesday Wednesday is the best scenario in Zealand, taking into account the existing work in GLP-1 and Amylin mechanisms.
The transaction closing in the second quarter will see Roche and Zealand, which equates Petrintide in US and Europe by 50/50. Elisel may have the right to exclusive commercialization in the world.
Next joint weight loss drug
Zelandiimma Pharma pointed to amylin analogues for a long time “The next generation” to treat weight loss. They work with hormone separated by the pancreas equal to insulin to increase saturation. It differs from GLP-1 agonists, which consists of hormones hormones for gestine hormones to suppress and regulate blood sugar.
“Petrolintide to help people faster than GLP-1,” Petrolintide “said to people,” Stensesberg said.
New treatment hopes that two companies will meet the heterogeneous of obesity treatment and the heterogeneous of its commercials, according to Rosh Chagravarth.
“It’s not just about weight
Petrolteitide is undergoing two tests, currently there are three phases plan. Senior companies said that companies will produce the product to the market until 2030.
Bota experts on Wednesday, Wednesday, Wednesday, Wednesday Petrolintide, Pharma’s Petrolintide, is the best of classes, as a monotherapy for 20% to 20%.
This comes after the second stage trials of Novo Norstisk Fun investors After the expected weight loss results on Monday.
The shares decreased by more than 6% after the last reading, and this drug helped adults with diabetes 2, their weight is less than 25% Previously assumed.